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Abstract
Background: Numerous studies reported genomic alterations in colorectal human tumors but few focused on
rectal tumors with the specification of preoperative-treated or untreated tumors. The goals of this study were to
list chromosome allelic imbalances and correlate their frequency with tumor progression and to identify potential
molecular markers of progression in rectal chromosomally unstable tumors without preoperative treatment.
Methods: Genomic alterations of 57 rectal tumors assessed by allelotyping targeting 33 chromosomal loci, were
clusterised and compared to those of 151 left colon tumors.
Results: Clustering separated the rectal tumors without preoperative treatment into three subtypes according to
the allelic imbalance frequency and genomic alteration associations. The tumors without preoperative treatment
displayed a significantly higher allelic imbalance frequency (54%) than the tumors with preoperative treatment
(33%), suggesting that treatment could target highly altered tumor clones. Interestingly, the survival analysis
identified three potential prognostic molecular survival markers, D1S197, D5S430, and D14S65, for tumors without
preoperative treatment.
Conclusion: Based on the genomic status of 33 chromosomal loci, we observed that rectal tumors without
preoperative treatment segregate according to the global allelic imbalance frequency but without correlation to
the tumor progression. Moreover, the detailed associations of alterations in rectal tumors are different from those
described in colon tumors suggesting that rectal and left tumors should be considered as separate entities. Finally,
potential prognostic genomic molecular markers for survival are proposed which status could specify the clinical
course of the tumors.
Background
Colorectal cancer is the second most common cause of
cancer deaths in the Western world after lung cancer
for men and breast cancer for women [1]. In 2000, in
France, the incidence of colorectal cancer was 36 300
patients, and there are approximately 12 000 new cases
of rectal cancers diagnosed per year [2,3].
A multistep process involving mutational events in
both oncogenes and tumor suppressor genes is now
accepted worldwide for the development of most
cancers. In the current model of the stepwise progres-
sion of colorectal carcinogenesis [4], each step is
initiated by the acquisition of additional genomic
abnormalities that confer a growth advantage to the tar-
geted cell. Because of the increasing complexity of the
combination of alterations observed during tumor pro-
gression, understanding the mechanisms underlying the
recurrences and invasiveness of early-stage cancers
remains of critical importance [5]. Although these chro-
mosome alterations have been extensively analyzed with
genome-wide chromosomal approaches, such as com-
parative genomic hybridization (CGH), reliable genomic
markers for characterizing the progression to malignant
stages or the resistance to treatment have yet to be
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ker with sufficient evidence to justify routine clinical
assessment is KRAS mutational analysis for EGFR-speci-
fic therapy decision-making [6]. For a better validation,
improvement in the tumor inclusion could be made, for
example, by discriminating the carcinoma localization or
phenotype. Indeed, several studies have suggested that
carcinomas from proximal, distal, or rectal sites [7] as
well as cancers of the microsatellite (MIN) and chromo-
somal unstable (CIN) phenotype [8] have different prop-
erties and should consequently be analyzed separately.
Surgery with total mesorectal excision with preserva-
tion of pelvic nerves is the mainstay of treatment, and
neoadjuvant chemoradiotherapy is presently considered
as the standard treatment of most T3-4 rectal cancers.
In France, a combination of radiotherapy (45 Gy/5
weeks) with concurrent capecitabine (1,600 mg/m
2)i s
the most popular protocol [9]. Preoperative treatment
significantly decreases the local recurrence rate, but has
no effect on the global survival and the metastasis pro-
gression rate [10].
In clinico-pathological and molecular studies, the
rectum is often considered as a part of the distal colon
rather than a separate entity. The few studies that ana-
lyzed mutations in key regulatory oncogenes and
tumor suppressor genes for sporadic cancer sites
showed a significant difference in mutation rates for
K-Ras, TP53, and APC, specifically between the rectum
and the rest of the colon [11,12]. However, the main
difficulty inherent to the molecular study of rectal
tumors is that they are often irradiated before surgery,
leading to potential genomic abnormality selection,
and, to our knowledge, the effects of radiochemother-
apy on the molecular phenotype of the tumors is not
well described [13].
The aim of our study was to determine whether the
frequency of genomic alterations could be correlated to
the tumor progression and to identify potential molecu-
lar markers for survival in a homogeneous cohort of
rectal chromosomally unstable tumors without preo-
perative treatment. In addition we aimed to compare
the genomic profiles of left and rectal tumors.
The tumor genomic alterations were evidenced by
means of the allelic imbalance at 33 microsatellites (MS)
mainly localized in chromosomal regions previously
described as being frequently altered in colorectal cancer
[14,15]. Allelotyping, based on a sensitive and automated
fluorescent-based DNA technology [16], is a fast, cheap,
and sensitive approach used in routine clinical diagnosis.
Using allelotyping and clustering of the data allowed
us to show that rectal tumors without preoperative
treatment segregate into three sub-types according to
the global allelic imbalance frequency but without corre-
lation to the tumor progression. Also, our data revealed
that according to the global AI frequency, left colon
tumors were distributed similarly to rectal tumors with-
out preoperative treatment, but were separated accord-
ing to the nature of the loci associated in the cluster
trees. These results reinforce the concept that colon and
rectal tumors are distinct entities.
Methods
Patients and tumor specimens
Tumor specimens and the clinical data obtained from
119 consecutive rectal tumors (83 men and 36 women
with an average age of 66.5 years (from 24 years to 89
years)) were obtained from the Surgical Department at
the University Hospital Hautepierre (Strasbourg-France)
from December 1996 to August 2006 according to the
French Ethical Committee recommendations. Staging,
angioinvasion, stromal inflammation and differentiation
of the tumors were evaluated at the Pathology Depart-
ment, after resection for tumors without preoperative
treatment and after the neoadjuvant therapy and resec-
tion for tumors with preoperative treatment. For tumors
without preoperative treatment, each sample contained
at least 40% of tumor cells as estimated by allelic imbal-
ance at loci known to be deleted (TP53, APC, 18q) and
by histopathological examination. All rectal tumors were
characterized through the use of endorectal echo-
endoscopy and/or a pelvic MRI, a thoraco-abdominal
scanner, or abdominal echography with a Thorax X-Ray
and peroperative observations. An emergency surgery
was carried out for 3 patients out of 119 (2.5%) for an
occlusive syndrome; in the other cases, the diagnosis
was confirmed with biopsies during colonoscopy. The
median follow-up was 25 months.
Allelotyping was performed for 57 patients (40 men
a n d1 7w o m e n )o u to ft h e1 1 9 ,w i t ha na v e r a g ea g eo f
66 years (from 34 years to 87 years of age). Of the 57
patients, 33 had no preoperative treatment and 24 had
undergone preoperative treatment (preoperative radio-
therapy, n = 16; preoperative radiochemotherapy, n = 8;
Table 1). No biopsies of the tumors before treatment
were available. To compare the distribution of genomic
alterations between left colon and rectal tumors, a
cohort of 151 left CIN colon tumors were included
whose TNM stages are indicated in Table 2.
The total dose of preoperative radiotherapy (RT) was
39 Gy in 13 fractions over 3 weeks. The dose per frac-
tion was 3 Gy. For patients who underwent radiotherapy
and concurrent chemotherapy (CT), the first CT cycle
was administered from days 1 to 5 of the RT treatment.
Fluorouracil (FU) at a dose of 350 mg/m
2/d was deliv-
ered for 20 minutes in 100 mL of saline infusion 1 hour
before RT. All relevant clinical and pathological charac-
teristics were collected and entered into a retrospective
database.
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Page 2 of 13DNA extraction and microsatellite amplification
DNA was extracted and amplified from patients’ blood,
frozen tumors, and normal mucosa sections by fluores-
cence PCR as described previously [17]. The panel of 33
MS targeting 17 chromosomes [18] allows for the
detection of at least 1 alteration in each tumor tested
and corresponds to the most frequently rearranged loci
in colon cancer [14,15]. Primers were obtained from
either the Genome DataBase http://www.gdb.org or
Genmap’99 http://www.ncbi.nlm.nih.gov/genemap99/.
Amplified fragments were analyzed on an ABI Sequen-
cer (Applied Biosystems(r), France SA) allowing a sensi-
tive and quantitative evaluation of the allele ratio by
measuring the peak height of both alleles. AIs were con-
firmed by a second independent PCR. Cut-off values for
significant AI were determined from previous studies
[17,19]. The allelotyping detects a change in the allele
ratio in the carcinoma relative to the allele ratio in
paired normal blood cells and normal mucosa [18].
A modification of the allele ratio in the carcinoma rela-
tive to the matched control is referred to as AI, and the
presence of an additional peak is referred to as MSI.
The locus AI frequency corresponds to the percentage
Table 1 Clinical and anatomo-pathological characteristics of rectal tumors analyzed for 33 microsatellites
With preoperative treatment (33 MS allelotyping)
n=2 4
Total tumors
n = 119
Without preoperative treatment (33
MS allelotyping) n = 33
With preoperative
radiotherapy n = 16
With preoperative radio-
chemotherapy n = 8
Age Median 66.5 years 69 years 68 years 61 years
Range [24; 89] [34; 87] [44; 82] [42; 68]
Sex Ratio Male 83 22 (66.7%) 11 (68%) 7 (87.5%)
Female 36 11 (33.3%) 5 (32%) 1 (12.5%)
UICC Staging 0-I 34 12 3
II 33 6 6
III 25 8 4
IV 27 7 11
Localization [0; 5 cm] 53 9 11 3
[5; 10 cm] 44 13 5 5
[10; 15 cm] 22 11 0 0
Stromal
Inflammation*
No
inflammation
81 (68.1%) 26 (78.8%) 14 (58.3%)
Inflammation 38 (31.9%) 7 (21.2%) 10 (41.6%)
Differenciation* Not
differentiated
4 (3.3%) 0 (0%) 2 (8.3%)
Middle
differentiated
39 (32.8%) 13 (39.4%) 7 (29.3%)
Well
differentiated
76 (63.9%) 20 (60.6%) 15 (62.5%)
Angio-invasion* No angio-
invasion
101 (84.9%) 26 (78.8%) 6 (25%)
Angio-
invasion
18 (15.1%) 7 (21.2%) 18 (75%)
Local recurrence
rate at 2 years
8.3% 6.1% 8.3%
Metastatic relapse
at 2 years
22.7% 18.1% 29.2%
2 years overall
survival
91% 89% 81%
MS = microsatellite, UICC = Union International Against Cancer - *These items were evaluated after resection for tumors without preoperative treatment and
after neoadjuvant therapy and resection for tumors with preoperative treatment.
Table 2 Characteristics of the 151 patients with left
colon tumors
Left colon tumors
Age Median 66 years
Range [37; 88]
Sex Ratio Male 90 (59.6%)
Female 61 (40.4%)
Stage UICC 0-I 22 (14.6%)
II 31 (20.5%)
III 27 (17.9%)
IV 71 (47%)
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cohort, whereas the mean global AI frequency corre-
sponds to the number of informative loci that are
altered within a cohort.
In order to exclude carcinomas with an MSI-H pheno-
type, the panel of five MS recommended by the U.S.
National Cancer Institute (BAT25, BAT26, D5S346,
D2S123, and D17S250) was included in the analysis
[20]. Homozygous, non-amplified, and MSI microsatel-
lites were considered as non-informative.
Statistical analyses
The variables were studied using c
2 and Fisher’se x a c t
tests for qualitative variables and the Student’s t-test for
quantitative variables. Survival analyses were analyzed by
a Kaplan-Meier test and no correction for multiple test-
ing was applied. The total threshold of significance was
fixed at 5%. To assess the independence of the prognosis
value of the survival markers, the Cox proportional
hazards model was fitted with a stepwise backward
method and with adjustment for confounding variables.
For clustering analysis, data were coded in binary form
using “1” for a locus in AI and “0” for a normal infor-
mative locus. Homozygous were treated as missing data.
Data were then clustered using a two-way unsupervised
clustering method and the analyses were run using the
uncentered correlation metric with complete linkage
clustering. No bootstrap method was used to assess the
stability of clusters. This analysis was carried out using
the Cluster 3.0 software. The cluster trees were pro-
duced using Java Tree View 1.0.4 (Eisen’s Softwares(r)).
All statistical analyses were performed with the Statisti-
cal Package for Social Sciences software (SPSS for Win-
dows version 11.5).
Results
Mean global AI frequency
Clinical data for 119 consecutive rectal tumors were
retrospectively analyzed. TNM stages, distribution, his-
tological data (stromal inflammation, differentiation,
angio-invasion), local recurrence rate, and two-year
overall and progression-free survivals (PFSs) were in
accordance with the literature [21]. The global local
recurrence rate at two years was 8.3% (6.9% for patients
without preoperative treatment and 9.7% for patients
with preoperative treatment); however, this difference
was not significant. The 2-year global survival rate was
91% for all patients. The 2-year progression-free survival
rate was 81% for patients with tumor stages inferior or
equal to III. Out of 119 tumors, 2 were MSI-H (1.7%)
and were excluded from the analysis.
Allelotyping was performed for 33 microsatellites on
57 rectal tumors of the CIN phenotype and all clinical
stages. Twenty-four tumors had preoperative treatment
and 33 tumors had no preoperative treatment. The
mean global AI frequency per tumor was 45% in the
cohort of 57 rectal tumors, and a significant decrease in
the frequency was observed between rectal tumors with-
out preoperative treatment (mean AI frequency 54%)
and rectal tumors with preoperative treatment (mean AI
frequency 34%, P =0 . 0 0 1 ,F i g u r e1 A ) .T h i sd i f f e r e n c e
remained significant (39%, P < 0.05) after removing
tumors that had lost all AIs after preoperative treatment
(n = 4/24). The number of tumors with at least one
MSI microsatellite was 26 out of 33 tumors without pre-
operative treatment (mean 5%) and 7 out of the 24
tumors with preoperative treatment (mean 4%).
Mean global AI frequency and clinical stages
No significant difference in the mean AI frequency was
observed between early (0/I/II) and late (III/IV) TNM
stages within each group of tumors (55% for stages 0/I/
II vs. 52% for stages III/IV without preoperative treat-
ment and 24% for stages 0/I/II vs. 33% for stages III/IV
with preoperative treatment; Figure 2B). However, when
comparing tumors with or without preoperative treat-
ment, the mean global AI frequency was significantly
different for stages 0/I/II (P <0 . 0 5 )a n ds t a g e sI I I / I V
(P < 0.05; Figure 1B).
Loci involved in tumor progression
In order to identify loci involved in the progression of
tumors without preoperative treatment, the locus AI fre-
quency was analyzed for each microsatellite according to
the stage of the tumors. The mean locus AI frequency
ranged from 25% to 82%. The 10 most altered loci dis-
played AI frequencies in excess of 60%: D5S346 (5q),
D8S264 (8p), D8S283 (8p), D9S171 (9p), D13S173 (13q),
TP53 (17p), D18S53 (18p), D18S61 (18q), D20S107
(20q), and D22S928 (22q) (Figure 1C), but no significant
correlation with the tumor stage was found.
Clustering analysis of genomic alterations for tumors
without preoperative treatment
To further characterize the associations of alterations
involved in tumor progression, we performed a two-way
hierarchical unsupervised clustering analysis of genomic
alterations in rectal tumors without preoperative treat-
ment. This analysis indicated three clusters of tumors
with distinct levels of CIN (Figure 2A). One cluster
(CIN Low or CIN-L) had tumors harboring a low num-
ber of alterations: on average 43% of the loci were
altered (27%-71%; n = 11), and they were mainly altered
at markers on 8p (D8S264), 17p (TP53, close to the p53
gene), 18q (D18S61, D18S53), and 20q (D20S107).
A second cluster of tumors (CIN-High or CIN-H) har-
bored a large number of alterations: on average 72.8% of
the loci were altered (38%-100%; n = 15), and the altera-
tions were widely distributed among all MS, but also
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Page 4 of 13Figure 1 Allelic imbalance frequency distribution. A) Global AI frequency in tumors without (n = 33) or with preoperative treatment (n = 24).
B) AI frequency for tumors without or with preoperative treatment according to TNM stages (UICC). C) AI frequency function of tumor TNM
stages according to the 10 most frequently altered loci in rectal tumors without preoperative treatment (n = 33).
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Page 5 of 13Figure 2 Two-way hierarchical clustering of allelotyping 33 rectal tumors. A) Clustering of 33 rectal tumors without preoperative treatment.
Vertical columns correspond to microsatellites, horizontal lines correspond to tumors. Red squares correspond to loci with allelic imbalance,
green squares to normal loci, and grey squares to non-informative. B) Stage distribution according to clusters CIN-VL, -L, and -H (n = 33).
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Page 6 of 13included alterations on 8p, 17p, 18q, and 20q. A third
cluster (CIN-very Low or CIN-VL) included tumors
with a very low number of alterations: on average 29%
of loci were altered (14%-48%; n = 7). The mean num-
ber of loci altered was significantly different between the
three clusters (CIN-H, -L, -VL, P < 0.05), but within a
cluster there was no significant correlation with a speci-
fic clinical stage (Figure 2B; 8 stages 0/I/II versus 7
stages III/IV in CIN-H; 5 stages 0/I/II versus 6 stages
III/IV in CIN-L, and 5 stages 0/I/II versus 2 stages III/
IV in CIN-VL) or with the global or progression-free
survival.
It should be noted that the alterations of D5S346
(informative for APC) and TP53 (informative for p53)
were not associated in the clustering tree.
Survival studies and genomic alterations
Identification of loci whose status could potentially
modulate global survival and progression-free survival
was performed by Kaplan-Meier analysis of tumors with
or without preoperative treatment.
Potential survival markers for tumors without preoperative
treatment
Among the 33 microsatellites analyzed for the 33
tumors without preoperative treatment, the status of
D1S197, D5S430, and D14S65 significantly influenced
survival. Tumors without AI at locus D1S197 had a
overall survival that was significantly higher (P < 0.05)
than those with AI (Figure 3A). Tumors with AIs at loci
D5S430 and D14S65 had a PFS that was significantly
higher (P < 0.05) than those with no AI (Figure 3B-C)
(Table 3). Neither sexe nor age was a independent prog-
nostic factor when adjusting the survival analysis of
these microsatellites in overall and in PFS (P > 0.3).
Potential survival markers for tumors with preoperative
treatment
Among the 33 microsatellites analyzed for the 24
tumors with preoperative treatment, a significant differ-
ence in global survival associated with D2S159, D9S179,
and D17S790 was observed (data not shown). Tumors
with no AI at these loci displayed a better global survi-
val than those with AIs at these loci (P < 0.05). On the
other hand, tumors without an AI at locus D2S159 but
with an AI at locus D6S264 had a better PFS (P <0 . 0 5 )
(Table 3).
Clustering analysis of 151 left allelotyped colon tumors
To discriminate genomic alterations between left colon
and rectal tumors without preoperative treatment, their
mean global AI frequency and alteration distribution
were compared. The mean global AI frequency was
identical for the 151 left colon tumors and for rectal
tumors (54% and 53.5%, respectively). The two-way hier-
archical clustering separated left colon tumors into three
clusters (CIN-H,-L, -VL; data not shown), as it did for
rectal tumors. Within each cluster, the mean global AI
frequency was similar for left colon and rectal tumors,
but was significantly different between the clusters (P <
0.01). When left colon and rectal tumors were combined
within the same cluster, the 2-way hierarchical cluster-
ing could not separate them (Figure 4A) and the mean
locus AI frequency for each of the 33 microsatellites
was not statistically different between both groups of
tumors (c
2 test).
As evidenced by the cluster trees and apart from the
panel of markers located on 8p, 18q, 17p, and 20q,
which aggregated as for the rectal tumors, combinations
of loci were different between left colon and rectal
tumors without preoperative treatment (Figure 4B-C).
For example, loci D5S430 and D3S1282 or D17S790 and
D17S794 were found to be associated in the clustering
tree of left colon tumors, but were not associated in the
rectal tumor tree; similarly, loci D5S430 and D2S159
were associated in the clustering tree of rectal tumors,
but not in that of left colon tumors (Figure 4B-C).
Discussion
The aim of the present work was to correlate the allelic
imbalance frequency and tumor progression, and to
compare AI distribution between left and rectal tumors.
Despite the small size of the cohort, no other studies, to
our knowledge, have analyzed a homogeneous collection
of rectal tumors. We also tempted to identify potential
molecular markers for survival in a cohort of rectal
chromosomally unstable tumors without preoperative
treatment.
Clustering of rectal tumors without preoperative treat-
ment distinguished three subtypes of tumors according
to the mean AI frequency at 33 chromosomal loci, but
independent of the tumor stage. These results suggest
that the potential for metastasis could be present very
early in tumor development.
Preoperative treatment and AI frequency
There was a significant decrease in the mean global AI
frequency of tumors with preoperative treatment as
compared with tumors without preoperative treatment,
even when those with no more alterations after preo-
perative treatment were excluded. To explain these AI
frequency differences between tumors with or without
preoperative treatment, one could hypothesize that the
clones that were sensitive to radiochemotherapy had a
high level of alterations, i.e., a high number of altered
chromosome loci. This suggests that within a tumor, the
treatment will target some specific sensitive chromoso-
mal loci. Unfortunately, biopsies of the tumors prior to
the treatment were not available, and comparison of
genomic alterations before and after treatment was not
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Page 7 of 13Figure 3 Event-free survival computed using the Kaplan and Meier method. The Kaplan-Meier survival curves were computed according to
allelic imbalances at loci D1S197, D5S430, and D14S65 for patients without preoperative treatment. A) Global survival according to locus D1S197
status. B) PFS according to locus D5S430 status. C) PFS according to locus D14S65 status.
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Page 8 of 13possible. Our observation is in agreement with Tannap-
fel et al. [13], who previously showed that the apoptotic
index increased and the proliferative activity decreased
significantly after radiochemotherapy in resected rectal
tumors as compared to pretreatment biopsies. A focus
on loci and their associated genes whose AI frequencies
are significantly different before and after preoperative
treatment would permit the specification of a set of
alterations that predict the sensitivity of a tumor to
treatment. Indeed, Tannapfel et al. [13] showed that
p53-deleted tumors generally exhibited a higher apopto-
tic index. However, as in our cohort, the preoperative
treatment did not efficiently eliminate clones with an
altered TP53 locus (82% vs. 50% of tumors with an
altered TP53 locus in tumors without and with preo-
perative treatment, respectively); the status of the TP53
locus did not specify the tumor sensitivity to preopera-
tive treatment. However, preoperative treatment might
decrease the global AI frequency by killing tumor clones
bearing numerous alterations, while clones with a low
level of alterations would resist the treatment.
On the other hand, although a correlation between
t h ep r o g r e s s i o no ft h et u m o rs t a g ea n dt h ei n c r e a s ei n
allelic imbalance was previously proposed [19,22], clus-
tering of the allelotyping performed for the primary
tumors and their matched metastasis showed that any
tumor stage could be associated with any frequency
[ 2 3 ] .T h e r e f o r e ,t h en u m b e ro fg e n o m i ca l t e r a t i o n s
could not predict the progression, and the invasive and
metastatic potential are probably present at an early
stage of tumor development.
Altered loci and associated genes
We identified 10 loci that were altered in more than 60%
of tumors with no preoperative treatment regardless of
the tumor stage: D5S346, 5q; D8S264, 8p; D8S283, 8p;
D9S171, 9p; D13S173,13q; TP53, 17p; D18S53, 18p;
D18S61, 18q; D20S107, 20q; and D22S928, 22q.
Allelotyping identifies chromosome loci rather than
specific genes and does not specify whether the
alteration corresponds to a deletion or a gain of a locus.
Despite these inconveniences, some of these loci target
genes that have been shown to be implicated in colorec-
tal carcinogenesis. It is well known that 18q is involved
in tumor progression. DCC [24] and SMAD4 [25] are
localized on 18q and are involved in colorectal carcino-
genesis. Accordingly, we found that 18q was frequently
altered in our cohort. Locus D18S61 (18q22) is close to
the Bcl-2 gene that codes for an anti-apoptotic and
oncogenic protein [26]. Conflicting data have been
reported for Bcl-2, as Charara et al. [27] demonstrated
that tumors overexpressing Bcl-2 displayed no residual
tumor in response to neoadjuvant chemoradiotherapy,
whereas Reerink et al. [28] found no relationship
between tumor response in chemoradiotherapy and the
level of Bcl-2 expression. This latter observation was
corroborated in a recent meta-analysis of rectal tumors
[29]. Evidence has been provided that another gene,
GNAL (G protein alpha), localized on 18p close to
D18S53, regulates several transforming functions that
are linked to the acquisition of aggressive phenotypes in
solid tumors [30].
The TP53 locus is informative for the p53 protein,
which is called the cellular “gatekeeper” for growth
and division [31], and this locus is lost early in the
progression from adenoma to carcinoma [32]. TP53
has been investigated as both a prognostic factor and a
predictor of the response to therapy, but with conflict-
ing results, as the study design made it difficult to
draw firm conclusions [27,33-35]. Therefore, the
European Group on Tumor Markers ruled it as insuffi-
cient evidence and did not recommend a routine use
for p53 as either a prognostic or predictive factor [36].
Indeed, in our cohort, although the altered TP53 fre-
quency decreased after preoperative treatment, the AI
frequency remained high (50%); thus, its status could
not be predictive of the sensitivity to preoperative
treatment. On the other hand, D5S346 is informative
for the APC gene, which promotes the degradation of
b-catenin and therefore limits the transcription of Wnt
Table 3 Distribution of prognostic molecular survival markers between patients with and without
preoperative treatment
Without preoperative treatment
(n = 33)
With preoperative treatment
(n = 24)
Global Survival D1S197
a D9S179
b
D17S790
b
D2S159
a
Progression Free Survival D14S65
a D2S159
a
D5S430
a D6S264
a
Loci with a good prognosis are indicated in bold when normal and are underlined when bearing AI.
ap < 0.05.
bp < 0.01.
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Page 9 of 13Figure 4 Two-way hierarchical clustering of allelotyping rectal and colon tumors. Vertical columns correspond to microsatellites, horizontal
lines correspond to tumors. Red squares correspond to loci with allelic imbalance, green squares to normal loci, and grey squares to non-
informative. A) Left colon tumors (n = 151) mixed with rectal tumors (n = 33). Dots correspond to rectal tumors without preoperative treatment.
B) Dendrogram of left colon tumors (cluster not shown). C) Dendrogram of rectal tumors without preoperative treatment (from Figure 2). For B)
and C) Arrows and dots: examples of loci associated in the left colon tumors but not associated in rectal tumors. Asterisks: loci associated in
rectal tumors but not in left colon tumors.
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Page 10 of 13target genes involved in regulating the cell cycle, chro-
mosome segregation and thus cell ploidy [37]. In col-
orectal tumorigenesis, APC has never been proposed
as a useful prognostic or predictive marker capable of
differentiating between patients; thus, changes in APC
status currently have no role in clinical practice. Loss
of the p-arm of chromosome 8 is frequently observed
in breast, prostate, and other types of cancers, and
among the genes located close to D8S264 is MYOM2,
whose expression is downregulated in breast cancer
[38]. Finally, D20S107 is close to DNA topoisomerase
I, a well-established molecular target of anticancer
drugs, such as camptothecin derivatives, which are
approved by the FDA for the treatment of colorectal
tumors. Topoisomerase I levels are not predictive of
drug cytotoxicity; rather, parameters downstream of
the cleavable complexes are critical for the cytotoxicity
of camptothecin [39].
Identification of putative prognostic markers of survival
The survival study identified three potential survival
prognostic markers for tumors without preoperative
treatment at loci D1S197, D5S430, and D14S65. From
a fundamental point of view, identification of the genes
targeted by these markers would be of interest to
understand how and which cellular alterations could
lead a tumor to spread over metastasis sites. For
instance, locus D1S197 is located on 1p32, a region
that is deleted in many tumors, notably in neuroblasto-
mas, colorectal and gastric cancers, and multiple endo-
crine neoplasia (MEN 2) [40]. A tumor suppressor
gene called FAS-associated factor 1 (FAF1) localized in
this region is involved in the regulation of apoptosis,
NFB activity [41], and neuronal cell survival [42], and
its downregulation may contribute to multiple aspects
of tumorigenesis. These data could justify that tumors
with AIs, and thus carrying a likely deletion at this
locus, may have a worse prognosis than tumors with a
normal locus. Locus D14S65 targets region 14q32.2, in
which vaccinia-related kinase 1 (VRK1) is localized.
This gene is implicated in cell metabolism and cell
proliferation, and its expression is increased in dividing
cells. Some studies have reported that the VRK1 pro-
tein is necessary for exit from G0, and the loss of
VRK1 could result in a block of cell cycle progression
in G1/S [43]. Thus, patients which tumors have a nor-
mal D14S65 locus might have a worse prognosis than
patients which tumors have this locus altered. Finally,
D5S430 targets, among others, the phosphatidylinosi-
tol-specific phospholipase C, X domain containing 3
(PLCXD3) gene, for which no function in carcinogen-
esis has been reported thus far. Of course, only real-
time PCR or CGH analyses would help to ascertain
valid candidate genes.
“Field effect” theory and colorectal carcinogenesis
The concept of cancer field effect has been proposed to
explain the occurrence of genetic and epigenetic mosai-
cism in cancer precursor tissues [44]. According to this
model, histologically normal adjacent tissue surrounding
the tumor should have at least some, but not all, of the
genetic alterations that are present in the fully devel-
oped cancer. These genetic alterations have been
described in many precancerous cells of various organs
(lung, breast, oesophagus, colorectal cancers...) and as
proposed by Heaphy et al. [45], could include AI as
shown in histologically normal breast tissues adjacent to
the tumors. This implies that there might be a reservoir
of genetically unstable cell clones within histologically
normal tissue, representing a fertile ground for tumor
development. The existence of these fields of genetically
altered cells, appearing histologically normal and dis-
ease-free, is consistent with the hypothesis that genomic
instability arises early in tumorigenesis. Thus, it could
be relevant to study the status of the D1S197, D5S430
and D14S65 loci in normal adjacent tissue of rectal
tumors. These loci might participate to the early step of
rectal tumor carcinogenesis.
Clustering of rectal cancer without preoperative
treatment
The two-way hierarchical analysis clustered the rectal
tumors without preoperative treatment into three clus-
ters, CIN-VL, CIN-L, and CIN-H, according to the
mean global AI frequency and loci associations. This
repartition corroborated the clustering of colon tumors
previously described by Weber et al. [23] as well as the
alterations at microsatellites D18S61, D8S264, D8S283,
and TP53, which are considered as early events in color-
ectal carcinogenesis [46]. In addition, there was no
correlation between the tumor stage and any of the
C I N - V L ,C I N - L ,a n dC I N - Hc l u s t e r s ,a n dt h es u r v i v a l
analysis did not reveal any significant differences
between clusters.
Clustering of rectal and left colon tumors
To assess the similarity of genomic alterations in left
colon and rectal tumors without preoperative treatment,
allelotyping data from both locations were clustered
together. The hierarchical cluster maintained the three
clusters based on the mean AI frequency, and the
tumors of the two origins did not segregate. However,
despite a common panel of alterations on 8p, 18q, 17p,
20q and no significant differences in the AI frequency at
each locus, we found that the loci that were associated
as clusters in left colon tumors differed from those in
rectal tumors, suggesting that rectal and left tumors
should be considered as separate entities. Similarly,
studies that investigated the mutational frequencies of
Romain et al. BMC Cancer 2010, 10:561
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Page 11 of 13K-Ras and APC or b-catenin and TP53 found differ-
ences between rectal and left colon tumors [11,47]. In
contrast, Slattery et al. [12] showed that rectal and distal
colon tumors share similar mutational frequencies for
p53, K-Ras mutations and for the CpG island methylator
phenotype, but differed from proximal colon tumors.
Conclusions
We evidenced that tumor progression in rectal carcino-
mas, instead of being related to the frequency of genomic
alterations at 33 chromosomal loci as assessed by allelo-
typing, could rather result from the disrupted functions
of the locus-associated genes specifying a capacity to dis-
seminate. Our data also identified some potential prog-
nostic genomic markers, for some of which the
associated genes remain to be identified. Their real impli-
cation as markers will require validation by a quantitative
method, such as real-time PCR, for a larger cohort of rec-
tal tumors. Finally, the pattern of alterations in rectal
tumors differ from those in colon tumors reinforcing the
concept that rectal and left tumors are separate entities.
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